Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (152)	3/5/1999 10:19:00 AM
From: AJAG	Read Replies (2) \| Respond to of 416

Headline- 3/5/99- Morgan Stanley raises target on Medimmune from 70 to 90. Check it out.

To: scaram(o)uche who wrote (152)	3/22/1999 9:54:00 AM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 416

richard. greetings from the BGEN board. for your info, medimmune is featured as the cover story in today's washington post bidnez section. for the record, i'm not a shareholder, simply local. -chris. ----- MedImmune Fights Off a Virus Maryland Biotech Firm Overcomes Early Disaster With Its Drugs for Babies By Justin Gillis Washington Post Staff Writer Monday, March 22, 1999; Page F12 Every month this winter, the McCaughey septuplets of Carlisle, Iowa, got a shot to protect them from a respiratory disease that can kill premature babies. Natalie, Alexis, Kenneth, Joel, Brandon, Kelsey and Nathan made it through the season in top form. washingtonpost.com